# Ultrafine Molybdenum Wire Braided Neurointerventional Implants: Bridging Biodegradability and Neurovascular Safety for Stroke Treatment

## TL;DR

This paper introduces biodegradable molybdenum wire implants that offer safe and effective stroke treatment without long-term toxicity.

## Contribution

The novel contribution is the development of ultrafine molybdenum wire implants that combine radiopacity, biodegradability, and neurovascular safety.

## Key findings

- Molybdenum implants showed negligible hemolysis and preserved coagulation kinetics in vitro.
- In vivo, Mo implants maintained blood homeostasis and neurological function without systemic toxicity.
- Molybdenum ions were cleared via the kidneys and did not accumulate in vital organs.

## Abstract

Neurovascular implants for stroke intervention face a critical dilemma: permanent devices (e.g., nitinol stents, platinum coils) often trigger chronic inflammation and recurrence, whereas biodegradable alternatives (Mg, Fe, Zn alloys) lack radiopacity or raise neurotoxicity concerns. Here, we introduce φ50 µm molybdenum (Mo) wire braided implants that integrate procedural efficacy with biological safety. Mo demonstrates negligible hemolysis (<5%), platelet‐inert surfaces, and preserved coagulation kinetics, together with robust cytocompatibility across neurovascular unit cells (endothelia, astrocytes, neurons) under both physiological and ischemia–reperfusion conditions. In vivo, Mo stent wires implanted in rodent carotids maintained blood homeostasis, organ integrity, and neurological function without systemic toxicity. Moreover, braided 2D Mo coils achieved durable aneurysm occlusion with controlled inflammatory resolution and progressive endothelialization, closely resembling clinical performance. Importantly, Mo ions showed no detectable accumulation in brain, kidney, lung, or spleen, attributable to renal clearance and blood–brain barrier selectivity. By coupling intrinsic radiopacity with homogeneous, moderate corrosion, Mo addresses long‐standing limitations of existing biodegradable alloys. These findings position Mo as a transformative candidate for next‐generation neurovascular devices, harmonizing biodegradability, safety, and imaging precision to redefine the management of both ischemic and hemorrhagic stroke.

Molybdenum (Mo), with its unique strength, uniform corrosion, and radiopacity, enables innovative biodegradable implants for transformative stroke therapy.